Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? Con position

Current Hypertension Reports

Volumn 4, Issue 4, 2002, Pages 311-318

  Ferdinand, Keith C ^a   Serrano, Claudia C ^b   Ferdinand, Daphne P ^b  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; ISOSORBIDE DINITRATE;

AFRICAN AMERICAN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; ETHNOLOGY; HUMAN; HYPERTENSION; NEGRO; REVIEW; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRALAZINE; HYPERTENSION; ISOSORBIDE DINITRATE; RISK FACTORS;

EID: 0036688313     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-996-0010-2     Document Type: Article

References (47)

1. Biostatistical fact sheet: African Americans and cardiovascular diseases. Dallas: American Heart Association; 1999.
2. Data fact sheet: Congestive heart failure in the United States: a new epidemic. Bethesda: National Heart Blood and Lung Institute; 1996.
3. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344: 1351-1357.
4. Yancy CW, Fowler MD, Colucci WS, et al.: Race and response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001, 344: 1358-1365.
5. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Inter Med 1997, 157: 2413-2466.
6. Cooper R, Rotimi C: Hypertension in blacks. Am J Hypertens 1997, 10(7 Pt 1): 804-812.
7. Ferdinand K: Management of minority patients with hypertension. In Hypertension Primer. Edited by Izzo J, Black H. Dallas: Lippincott Williams and Wilkins; 1999: 413-414.
8. Sacks FM, Svetkey LP, Vollmer WM, et al., for the DASH-sodium collaborative research group: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001, 344: 3-10.
9. Svetkey LP, Simmons-Morton D, Vollmer WM, et al.: Effects of dietary patterns on blood pressure: subgroup analysis of the dietary approaches to stop hypertension (DASH) randomized clinical trial. Arch Intern Med 1999, 159: 285-293.
10. Svetkey LP, McKeown SP, Wilson AF: Heritability of salt sensitivity in black Americans. Hypertension 1996, 28: 854-858.
11. ALLHAT collaborative research group: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283: 1967-1975.
12. Agodoa L, Appel L, Bakris G, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001, 285: 2719-2728.
13. Papademetriou V: Selection of antihypertensive therapy for patients with hypertensive renal disease [editorial]. JAMA 2001, 285: 2774-2776.
14. Clark L, Ferdinand K, Flack J, Gavin III J: Coronary heart disease in African Americans. Heart Dis 2001, 3: 97-108.
15. Liao Y, Cooper RS, McGee DL, et al.: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995, 273: 1592-1597.
16. Stone PH, Thompson B, Anderson HV, et al, for the TIMI III registry study group: Influence of race, sex and age on management of unstable angina and non-Q wave myocardial infarction. JAMA 1996, 275: 1104-1112.
17. Scirica BM, Moliterno DJ, Every NR, et al., for the GUARANTEE investigators: Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J 1999, 138: 1065-1072.
18. Maynard C, Fisher LD, Passamami ER: Survival of black persons compared with white persons in the coronary artery surgery study (CASS). Am J Cardiol 1987, 60: 513-518.
19. Strong JP, Malcolm GT, Oalmann MC, et al.: The PDAY study: natural history, risk factors and pathobiology. Pathobiological determinants of atherosclerosis in youth. Ann N Y Acad Sci 1997, 811: 226-235.
20. Weir MR, Gray JM, Paster R, Saunders E: Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients, The Trandolapril Multicenter Study Group. Hypertension 1995, 26: 124-130.
21. Ofili E, Flack J, Gibbons G: Race and responsiveness to drugs for heart failure. N Engl J Med 2001, 345: 766-768.
22. National Heart Lung and Blood Institute: NHLBI-VA study finds no increased survival from beta-blocker for moderate to advanced heart failure. Bethesda: NIH Press Release; May 30, 2001.
23. Carson P, Fowler M, Mohacsi P, et al.: Effect of carvedilol in black patients with severe chronic heart failure: results of the COPERNICUS study [abstract]. Paper presented at Sessions of the American Heart Association. Anaheim, CA. November 11-14, 2001.
24. Vasodilator-Heart Failure Trial Study Group: The vasodilator-heart failure trials (V-HeFT). Circulation 1993, 87(6 Suppl): VI1-117.
25. Carson P, Ziesche S, Johnson G, Cohn JN: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group (VHeFT I and II trials). J Cardiac Fail 1999, 5: 178-187.
26. AHeFT study group: African-American heart failure trial. J Cardiac Fail, In press.
27. Schwartz RS: Racial profiling in medical research. N Engl J Med 2001, 344: 1392-1393.
28. McNamara DM, Holubkob R, Postava L, et al.: Pharmacogenetic interactions of the ACE deletion polymorphism and high dose ACE inhibitor therapy in heart failure survival. Abstract. Circulation 2001, 104: II-594.
29. McNamara DM, Holubkov R, Janosko K, et al.: Pharmacogenetic interactions between beta blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001, 103: 1644-1648.
30. Cardillo C, Kilcoyne CM, Cannon RO, Panza JA: Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 1998, 31: 1235-1239.
31. Loscalzo J, Welch G: Nitric oxide and the cardiovascular system. Prog Cardiovasc Dis 1995, 35: 87-104.
32. Mahlab DS, Postava LA, Holubkov R, et al.: Beta 2 adrenergic receptor variant Ile 164: effect on heart failure survival and impact of beta blockade [abstract]. Paper presented at American College of Cardiology Meeting. Atlanta, GA. March 17-20, 2002.
33. McNamara DM, Holubkov R, Postava LA, et al.: Polygenic risk assessment improves usefulness of genotyping in heart failure populations: additive effects of ACE and ENOS polymorphism [abstract]. Paper presented at American College of Cardiology Meeting. Atlanta, GA. March 17-20, 2002.
34. Postava L, Holubkov R, Janosko KM, et al.: The aldosterone synthase protomer polymorphism modulates the effect of the ACE-D allele on heart failure survival [abstract]. Circulation 2001, 104: II-2.
35. Stephen T, Schwartz GL, Arlene B, et al.: C825T Polymorphism of the G protein ß3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001, 37: 739-743.
36. Gainer JV, Nadeau JH, Ryder D, et al.: Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996, 98: 283-287.
37. Physician's Desk Reference, 56th edn. Montvale, NJ: Medical Economics; 2002.
38. Brown NJ, Ray WA, Snowden M, Griffin MR: Black Americans have an increased rate of angiotensin-converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996, 60: 8-13.
39. Cushman WC, Reda DJ, Perry HM, et al., for the department of Veterans Affairs Cooperative Study Group on antihypertensive agents: Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med 2000, 160: 825-831.
40. The SOLVD investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327: 685-691.
41. The SOLVD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325: 293-302.
42. Pitt B, Poole-Wilson P, Martinez S, et al.: Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the losartan heart failure survivaltrial - ELITE II. J Cardiac Fail 1999, 5: 146-154.
43. Cohn JN: Baseline demographics of the Valsartan heart Failure Trial (Val-HeFT). Val-HeFT investigators. Eur J Heart Fail 2000, 2: 439-446.
44. Domanski M: Beta-blocker evaluation of survival trial (BEST trial). N Engl J Med 2001, 344: 1659-1667.
45. Goldstein S: Clinical studies on beta blockers and heart failure preceding the MERIT-HF trial. Metoprolol CR/XL. Randomized intervention trial in heart failure. AM J Cardiol 1997, 80: 50J-53J.
46. Le Jemtel TH: Review of the cardiac insufficiency bisoprolol study II (CIBIS II). Curr Cardiol Rep 1999, 1: 29-30.
47. Packer M, Bristow M, Cohn JN, et al.: The effect of carvedilol on survival and hospitalization for cardiovascular complications in patients with chronic heart failure. N Engl J Med 1996, 334: 1349-1355.